Fries J F
Am J Med. 1985 Jan 21;78(1A):12-4. doi: 10.1016/0002-9343(85)90239-6.
Studies that try to associate immunoinflammatory disease, typified by rheumatoid arthritis, and malignancy have been limited by several important methodologic difficulties. Usually the hypothesis examined has been one of an increase in incidence of one or more specific neoplasms, and sometimes this hypothesis has been generated after examining the data. Some of the more common methods for assessing risk, including case reports and small series, case-control studies, hospital-based studies, and animal studies, and the competing risk fallacy can create problems of interpretation and can skew the results. The ideal study is one in which a random sample of 1,000 or more patients with rheumatoid arthritis are followed prospectively from disease onset to death and the data compared with total population data over the same period. Ideally, there would be perfect follow-up and autopsy information available on all patients and all control patients. Such studies of course will not be available. However, those studies that are designed best fail to associate rheumatoid arthritis with malignancy, although certain specific malignancies do appear associated with alkylating agent therapy for rheumatoid arthritis.
试图将以类风湿性关节炎为代表的免疫炎性疾病与恶性肿瘤联系起来的研究,受到了几个重要方法学难题的限制。通常所检验的假设是一种或多种特定肿瘤发病率的增加,有时这个假设是在检验数据之后才产生的。一些较为常见的评估风险的方法,包括病例报告和小样本系列研究、病例对照研究、基于医院的研究以及动物研究,以及竞争风险谬误,可能会造成解释上的问题并使结果产生偏差。理想的研究是对1000名或更多类风湿性关节炎患者从疾病发作到死亡进行前瞻性跟踪,并将数据与同期的总人口数据进行比较。理想情况下,所有患者和所有对照患者都能获得完善的随访和尸检信息。当然,这样的研究是无法获得的。然而,那些设计得最好的研究未能将类风湿性关节炎与恶性肿瘤联系起来,尽管某些特定的恶性肿瘤确实似乎与类风湿性关节炎的烷化剂治疗有关。